Anti-BCL11B antibodies are used in the immunodetection of the protein BCL11 transcription factor B. In humans, the canonical protein has a reported length of 894 amino acid residues and a mass of 95.5 kDa. Its subcellular localization is in the nucleus. Up to 2 different isoforms have been reported for this protein. It is reported to be highly expressed in the brain and in malignant T-cell lines derived from patients with adult T-cell leukemia/lymphoma. BCL11B is a reported key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals.
The BCL11B marker can be used to identify Early T Lineage Precursor Cells, Specified Double Negative Thymocytes, Committed Double Negative Thymocytes, and Rearranging Double Negative Thymocytes.* Synonyms for this target antigen include B cell CLL/lymphoma 11B, B-cell CLL/lymphoma 11B (zinc finger protein), B-cell CLL/lymphoma 11B/T-cell receptor delta constant region fusion protein, and B-cell lymphoma/leukemia 11B. Over 100 citations in the literature describe the use of BCL11B antibodies in research. Western Blot is a widely used application for these antibodies. Immunocytochemistry and Immunohistochemistry are also common applications.
*HuBMAP Human Reference Atlas v1.4